| Camille Marie Bradley, MD | |
|
6301 Gaston Ave, Ste 300, Dallas, TX 75214-3922 | |
| (469) 800-7900 | |
| (469) 800-7910 |
| Full Name | Camille Marie Bradley |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 6301 Gaston Ave, Dallas, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427316322 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | Q3430 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor University Medical Center | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthtexas Provider Network | 1355254210 | 1810 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.
Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.
Oklahoma residents going to the polls June 30 have the chance to override state leaders' decade-long refusal to expand Medicaid, which would cover more than 200,000 low-income adults and bring billions of federal dollars into the state.
› Verified 2 days ago
| Entity Name | Lamb Healthcare Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700854288 PECOS PAC ID: 6103738471 Enrollment ID: O20040127000737 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.
Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.
Oklahoma residents going to the polls June 30 have the chance to override state leaders' decade-long refusal to expand Medicaid, which would cover more than 200,000 low-income adults and bring billions of federal dollars into the state.
› Verified 2 days ago
| Entity Name | Healthtexas Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760488936 PECOS PAC ID: 1355254210 Enrollment ID: O20040727001187 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.
Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.
Oklahoma residents going to the polls June 30 have the chance to override state leaders' decade-long refusal to expand Medicaid, which would cover more than 200,000 low-income adults and bring billions of federal dollars into the state.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Camille Marie Bradley, MD 6301 Gaston Ave, Ste 300, Dallas, TX 75214-3922 Ph: (469) 800-7900 | Camille Marie Bradley, MD 6301 Gaston Ave, Ste 300, Dallas, TX 75214-3922 Ph: (469) 800-7900 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.
Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.
Oklahoma residents going to the polls June 30 have the chance to override state leaders' decade-long refusal to expand Medicaid, which would cover more than 200,000 low-income adults and bring billions of federal dollars into the state.
› Verified 2 days ago
Dr. Juan F Quiroz, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4811a Columbia Ave, Dallas, TX 75226 Phone: 214-823-5590 Fax: 214-823-6638 | |
Dr. Michelle Dobbs, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6333 E Mockingbird Ln, Suite 126, Dallas, TX 75214 Phone: 214-826-6005 | |
Howard J Huntzinger, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9250 Amberton Pkwy, Dallas, TX 75243 Phone: 682-236-3656 | |
Robert J Dimeff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8081 Walnut Hill Ln, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 | |
Pardeep K Shori, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7012 La Vista Dr, Dallas, TX 75214 Phone: 817-564-5761 | |
Mary Elizabeth Wilcox Smith, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2921 Fairmount St, Dallas, TX 75201 Phone: 214-742-9310 | |
Elizabeth Chapek, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 6760 Abrams Rd, Suite 203, Dallas, TX 75231 Phone: 214-341-8742 |